New monoamine oxidase inhibitor type B Azilect® in treatment of Parkinson's disease


Cite item

Full Text

Abstract

According to modern concepts, the early use of symptomatic therapy in Parkinson's disease (PD) has a favorable effect on the motor function, as well as the quality of life of patients, decrease the risk of motor fluctuations and dyskinesias on the progression of the disease. Razagilin (Azilekt) is a high effective long-lasting irreversible inhibitor of type B monoamine oxidase. The drug has a good symptomatic effect as monotherapy in early stages PD and in combination with levodopa therapy for the full-scaled disease states, has a neuroprotective effect and modifies the course of the disease. Azilekt important features are: single daily intake without dose titration, no need for dose adjustment in elderly people. The use of the drug at different stages PD in various age patients is effective due to lack of effect on cognitive function, behavior and temper.

About the authors

N V Fedorova

N V Fedorova

References

  1. Иллариошкин С.Н. Новый ингибитор МАО-В разагилин - препарат для патогенетического и симптоматического лечения болезни Паркинсона. Обзор // Атмосфера. Нервные болезни. 2008. № 3. С. 7-12.
  2. Левин О.С. Применение нового ингибитора МАО-В - разагилина для лечения моторных флуктуаций при болезни Паркинсона. Обзор // Журнал неврологии и психиатрии им. С.С. Корсакова. 2008. № 9. С. 91-96.
  3. Akao Y, Maruyama W, Yi H, et al. An anti-Parkinson's disease drug, N-propargyl-1-(R)-aminoindan (rasogilin), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 2002;326:105-08.
  4. Bar Am O, Amit T, Youdim MBH. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drag rasagiline and selegiline. Neurosc Lett 2004;355:169-72.
  5. Blandini F. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease? CNS Drug Rev. 2005;11:183-94.
  6. Chaudhuri KR, Healy DG, Schapira AH. National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-45.
  7. Chen JJ, Ly AV. Pasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. Am J Health Syst Pharm 2006;63:915-28.
  8. Elmer L, Schwid S, Eberly S, et al. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci 2006;248:78-83.
  9. Fhan S, Oakes O, Shoulson I, et al. Levodopa and progression of Parkinson's disease. N Engl J Med 2004;351:2498-08.
  10. Getz CG, Poewe W, Rascol O. Mov Disordes 2005;20(5):523-39.
  11. Grosset D, Taurah L, Burn DJ. J Neurol Neurosurg Psychiatry 2007;78:465-69.
  12. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of joint task force of the EFNS and MDS-ES. Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006;13:1186-202.
  13. Horstink M, Tolosa E, Bonucelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the EFNS and MDS-ES. Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006;13(11):1170-85.
  14. Jenner P, Youim MHB, eds. Neurodegeneration and neuroprotection in Parkinson's disease. - London - Academic Press 1996:202-220.
  15. Knoll J. The pharmacology of selegiline (-)deprenil). New aspects. Acta Neurol. Scand. 1989;126(Suppl.):83-91.
  16. Leber P. Slowing the progression of Alzheimer disease: methodological issues. Alzheimer Dis Assoc Disord 1997;11(Suppl. 5):10-21.
  17. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 1995;311(7020):1602-07.
  18. Lev N, Dialdetti R, Melamed E. Initiation of symptomatic therapy in Parkinson's disease: dopamine agonists vs. levodopa. J Neurol 2007;254(Suppl. 5):19-26.
  19. Lew MF, Hauser RA, Hurtig HI, et al. and the TEMPO Extension Study Group. Long-term efficacy of rasagiline in Parkinson's disease patients. Parkinsonism Relat Disord 2005;11(Suppl. 2):129.
  20. Mandel S, Weinred O, Amit T, et al. Mechanism of neuroprotective action of the anti-Parkinson drug and its derivatives. Brain Res Rev 2005;48:379-87.
  21. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of Quality Standards Subcommittee of American Academy of Neurology. Neurology 2002;58:11-17.
  22. Obeso AHV. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59(3):559-65.
  23. Olanov CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19:997-1005.
  24. Olanow CW, Hauser R, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008;DOI:10:1002.
  25. Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: Treatment of Parkinson's disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-95.
  26. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol 2004;61:561-66.
  27. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson's disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-48.
  28. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DADATOP patients requiring levodopa. Ann. Neurol 1996;39:37-45.
  29. Rascol O. Expert Opin Pharmacother 2005;6:2061.
  30. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO study). Lancet 2005;365:947-54.
  31. Rascol O, Payoux P, Ory F, et al. Limitations of current Parkinson's disease therapy. Ann Neurol 2003;53(Suppl. 3):513-515.
  32. Samii A, Nutt JG, Ranson BR. Parkinson's disease. Lancet 2004;363:1783-94.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies